TRANSLOCATION t(3;12)(q26;q21) IN JAK2V617F POINT
MUTATION NEGATIVE CHRONIC IDIOPATHIC
MYELOFIBROSIS: A CASE REPORT
Mešanović S. Šahović H. Perić M.
*Corresponding Author: Semir Mešanović, Ph.D., University Clinical Center Tuzla, Polyclinic for laboratory diagnostic,
Department of Pathology, Trnovac bb, 75000 Tuzla, Bosnia and Hezegovina. Tel.: +387-35-303-509. E-mail:
semir.mesanovic@ukctuzla.ba
page: 63
|
|
REFERENCES
1. Jaffe ES, Harris NL, Stein H, Vardiman JW,
Eds. Pathology and Genetics of Tumours of
Haematopoietic and Lymphoid Tissues. World
Health Organization Classification of Tumours,
vol 3. Lyon, France: IARC Press, 2001.
2. Heim S, Mitelman F, Eds. Chronic myeloproliferative
didorders. In: Cancer Cytogenetics:
Chromosomal and Molecular Genetic Aberrations
of Tumor Cells, 2nd ed. New York, NY:
Wiley-Liss. 1995: 166-172.
3. Reilly JT, Snowden JA, Spearing RL, Fitzgerald
PM, Jones N, Watmore A, et al. Cytogenetic
abnormalities and their prognostic significance
in idiopathic myelofibrosis: A study of 106 cases.
Br J Haematol. 1997; 98(1): 96-102.
4. Dupriez B, Morel P, Demory JL, Simon M,
Plantier I, Bauters F. Prognostic factors in agnogenic
myeloid metaplasia: A report on 195
cases with a new scoring system. Blood. 1996;
88(3): 1013-1018.
5. Baxter EJ, Scott LM, Campbell P, East C, Forouclas
N, Swanton S, et al. Acquired mutation
of the tyrosine kinase JAK2 in human
myeloproliferative disorders. Lancet. 2005;
365(9464): 1054-1061.
6. Kralovics R, Passamonti F, Buser AS, Teo SS,
Tiedt R, Passweg JR, et al. A gain of function
mutation of JAK2 in myeloproliferative disorders.
N Engl J Med. 2005; 352(17): 1779-1790.
7. Levine RL, Wadleigh M, Cools J, Ebert BL,
Wernig G, Huntly BJ, et al. Activating mutation
in the tyrosine kinase JAK2 in polycythemia
vera, essential thrombocythemia, and
myeloid metaplasia with myelofibrosis. Cancer
Cell. 2005; 7(4): 387-397.
8. Steensma DP, Dewald GW, Lasho TL. The
JAK2 V617F activating tyrosine kinase mutation
is an infrequent eventh in both “atypical”
myeloproliferative disorders and myelodisplastic
syndromes. Blood. 2005; 106(4): 1207-1209.
9. Huret JL. t(3;12)(q26;q21). Atlas Genet Cytogenet
Oncol Haematol. 2007. (http://AtlasGeneticsOncology.
org/Anomalies/t0312q26q-
21ID1280. html).
10. Shaffer LG, Tommerup N, Eds. An International
System for Human Cytogenetic Nomenclature.
Basel, Switzerland: S. Karger, 2005.
11. Andrieux J, Demory JL, Morel P, Plantier I,
Dupriez B, Caulier MT, et al. Frequency of
structural abnormalities of the long arm of
chromosome 12 in myelofibrosis with myeloid
metaplasia.Cancer Genet Cytogenet. 2002;
137(1): 68-71.
12. Nunoda K, Sashida G, Ohyashiki K, Kodama A,
Fukutake K. The translocation (4;12)(q31;q21)
in myelofibrosis associated with myelodysplastic
syndrome: Impact of the 12q21 breakpoint.
Cancer Genet Cytogenet. 2006; 164(1): 90-91.
13. Przepiorka D, Bryant E, Kidd P. Idiopathic myelofibrosis
in blast transformation with 4;12
and 5;12 translocation and a 7q deletion. Cancer
Genet Cytogenet. 1988; 30(1): 139-144.
14. Cho HS, Hyun MS. A novel jumping translocation
of 12q21 in a patient with chronic idiopathic
myelofibrosis. Korean J Hematol. 2006;
41(2): 99-104.
15. Poppe B, Dastugue N, Vandesompele J, Cauwelier
B, De Smet B, Yigit N, et al. EVI1 is
consistently expressed as principal transcript
in common and rare recurrent 3q26 rearrangements.
Genes Chromosomes Cancer. 2006;
45(4): 349-356.
16. Kvasnicka HM, Thiele J, Werden C, Zankovich
R, Diehl V, Fischer R. Prognostic factors in idiopathic
(primary) osteomyelofibrosis. Cancer.
1997; 80(4): 708-719.
17. Jones AV, Kreil S, Zoi K. Waghorn K, Curtis C,
Zhang L, et al. Widespread occurrence of the
JAK2 V617F mutation in chronic myeloproliferative
disorders. Blood. 2005; 106(6): 2162-2168.
18. Ahmed A, Chang CC. Chronic idiopathic myelofibrosis.
Arch Pathol Lab Med .2006; 130(8):
1133-1143.
|
|
|
|
 |
Number 27
VOL. 27 (2), 2024 |
Number 27
VOL. 27 (1), 2024 |
Number 26
Number 26 VOL. 26(2), 2023 All in one |
Number 26
VOL. 26(2), 2023 |
Number 26
VOL. 26, 2023 Supplement |
Number 26
VOL. 26(1), 2023 |
Number 25
VOL. 25(2), 2022 |
Number 25
VOL. 25 (1), 2022 |
Number 24
VOL. 24(2), 2021 |
Number 24
VOL. 24(1), 2021 |
Number 23
VOL. 23(2), 2020 |
Number 22
VOL. 22(2), 2019 |
Number 22
VOL. 22(1), 2019 |
Number 22
VOL. 22, 2019 Supplement |
Number 21
VOL. 21(2), 2018 |
Number 21
VOL. 21 (1), 2018 |
Number 21
VOL. 21, 2018 Supplement |
Number 20
VOL. 20 (2), 2017 |
Number 20
VOL. 20 (1), 2017 |
Number 19
VOL. 19 (2), 2016 |
Number 19
VOL. 19 (1), 2016 |
Number 18
VOL. 18 (2), 2015 |
Number 18
VOL. 18 (1), 2015 |
Number 17
VOL. 17 (2), 2014 |
Number 17
VOL. 17 (1), 2014 |
Number 16
VOL. 16 (2), 2013 |
Number 16
VOL. 16 (1), 2013 |
Number 15
VOL. 15 (2), 2012 |
Number 15
VOL. 15, 2012 Supplement |
Number 15
Vol. 15 (1), 2012 |
Number 14
14 - Vol. 14 (2), 2011 |
Number 14
The 9th Balkan Congress of Medical Genetics |
Number 14
14 - Vol. 14 (1), 2011 |
Number 13
Vol. 13 (2), 2010 |
Number 13
Vol.13 (1), 2010 |
Number 12
Vol.12 (2), 2009 |
Number 12
Vol.12 (1), 2009 |
Number 11
Vol.11 (2),2008 |
Number 11
Vol.11 (1),2008 |
Number 10
Vol.10 (2), 2007 |
Number 10
10 (1),2007 |
Number 9
1&2, 2006 |
Number 9
3&4, 2006 |
Number 8
1&2, 2005 |
Number 8
3&4, 2004 |
Number 7
1&2, 2004 |
Number 6
3&4, 2003 |
Number 6
1&2, 2003 |
Number 5
3&4, 2002 |
Number 5
1&2, 2002 |
Number 4
Vol.3 (4), 2000 |
Number 4
Vol.2 (4), 1999 |
Number 4
Vol.1 (4), 1998 |
Number 4
3&4, 2001 |
Number 4
1&2, 2001 |
Number 3
Vol.3 (3), 2000 |
Number 3
Vol.2 (3), 1999 |
Number 3
Vol.1 (3), 1998 |
Number 2
Vol.3(2), 2000 |
Number 2
Vol.1 (2), 1998 |
Number 2
Vol.2 (2), 1999 |
Number 1
Vol.3 (1), 2000 |
Number 1
Vol.2 (1), 1999 |
Number 1
Vol.1 (1), 1998 |
|
|
